Home › Metabolic › Retatrutide (20mg)
Metabolic Research Peptide
GLP-1/GIP/Glucagon triple agonist · Research-grade, Australia
In stock · dispatched Australia-wide
View & buy on store →Retatrutide is a novel triple agonist peptide targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. This 20mg presentation is offered for extended laboratory studies of metabolic regulation, energy homeostasis, and adipose tissue metabolism in pre-clinical models.
Retatrutide is a triple agonist, acting at the GIP, GLP-1 and glucagon receptors, and that makes it an awkward compound to study in small quantities. Separating the contribution of three receptor pathways generally requires parallel arms — agonist alone, agonist with each receptor blocked, vehicle controls — and each arm consumes material. The 20 mg presentation is the smallest format that comfortably supports a multi-arm design on one lot, which is the point at which between-batch purity differences stop being a variable in the result.
| Compound | Retatrutide |
|---|---|
| Category | Metabolic |
| CAS Number | 2381089-83-2 |
| Form | Lyophilised Powder |
| Appearance | White to off-white solid |
| Purity | 99.537% (this batch) |
| Batch | CS-re20815 |
| Analytical methods | HPLC (purity), mass spectrometry (identity) |
| Solubility (research) | Reconstitutes in bacteriostatic or sterile water |
Batch-specific analytical values are recorded on the Certificate of Analysis supplied with the compound.
Retatrutide is supplied as a lyophilised powder and reconstitutes in bacteriostatic or sterile water. At 20 mg the vial holds enough material that stock concentration should be chosen deliberately rather than by default: a 1 mL reconstitution yields a 20 mg/mL stock that will need several dilution steps before it reaches assay range, while 4 mL yields 5 mg/mL, which is closer to working range and reduces cumulative pipetting error.
Stock concentrations from a single 20 mg vial:
| 1 mL of diluent | 20 mg/mL stock |
|---|---|
| 2 mL of diluent | 10 mg/mL stock |
| 4 mL of diluent | 5 mg/mL stock |
| 5 mL of diluent | 4 mg/mL stock |
In-vitro stock concentrations for laboratory dilution work. Not dosing information.
Retatrutide is stocked in four masses and they differ only in fill weight. The 10 mg vial is the entry format for a single characterisation run. This 20 mg vial is the multi-arm format — enough for parallel receptor-blockade arms and controls on one batch number. The 30 mg and 40 mg vials are for longitudinal and high-replicate work respectively, where aliquot-and-freeze is the working assumption from the outset.
One practical note on choosing between them: because the 28-day post-reconstitution window runs from the moment diluent is added regardless of vial size, a larger vial is only an advantage if the study can consume it inside that window or the material is aliquoted and frozen straight away. Buying up a format that then sits reconstituted is a false economy.
Every batch supplied by Vital Research Labs is analysed by an independent third-party laboratory. Purity is confirmed by high-performance liquid chromatography (HPLC) and identity by mass spectrometry (MS). This batch is verified at 99.537% purity, and a Certificate of Analysis is available for the batch so researchers can verify exactly what they are working with.
Retatrutide is dispatched from within Australia to Australian research customers, packaged discreetly and appropriately for a lyophilised research compound. Orders are processed on receipt of payment via bank transfer.
Yes. Vital Research Labs supplies research-grade Retatrutide (20mg) to Australian research customers, dispatched domestically. It is provided strictly for in-vitro laboratory research and is not for human or veterinary use.
This batch is verified at 99.537% purity by third-party analytical testing (HPLC for purity, mass spectrometry for identity). A Certificate of Analysis is available for the batch.
Each batch is analysed by an independent third-party laboratory using HPLC to confirm purity and mass spectrometry to confirm identity. Batch-specific values are recorded on the Certificate of Analysis.
The lyophilised powder is stored at -20 degrees C, protected from light and moisture. Once reconstituted for research it is kept at 2-8 degrees C and typically used within 28 days.
No. Retatrutide (20mg) supplied by Vital Research Labs is intended strictly for in-vitro laboratory research and development. It is not a medicine or therapeutic good and is not for human consumption, veterinary use, or clinical application.
Vital Research Labs supplies Retatrutide from Australian stock, dispatched from New South Wales. Orders placed before the daily cut-off are dispatched the same business day, Monday to Friday, with tracked delivery Australia-wide including Sydney, Melbourne, Brisbane, Perth and Adelaide.
Orders are dispatched the same business day payment is confirmed, Monday to Friday. Weekend and public holiday orders are dispatched the next business day. Standard and express options are available, and express shipping is free on orders over $200. Every order is sent tracked.
Yes. All orders are packed in plain, unbranded outer packaging with no indication of the contents, and sent tracked via Australia Post or an equivalent carrier.
We accept Visa, Mastercard and American Express, plus Apple Pay and Google Pay, all taken instantly at checkout. Bank transfer is also available if you prefer.
Reconstituting 20mg in 1mL of bacteriostatic water gives 20mg/mL; 2mL gives 10mg/mL; 4mL gives 5mg/mL; and 5mL gives 4mg/mL. These are in-vitro stock concentrations for laboratory dilution work only.
The 10mg vial suits a single characterisation run. The 20mg vial suits a multi-arm design where parallel receptor-blockade arms and controls all need to come from one lot. The 30mg and 40mg vials suit longitudinal and high-replicate work. All four are the same compound and differ only in fill weight.
Because separating the contribution of the GIP, GLP-1 and glucagon receptor pathways requires parallel experimental arms rather than one. Agonist alone, agonist with each receptor blocked, and vehicle controls each consume material, so a design that resolves three pathways draws several times what a single-receptor characterisation would.